[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatic-steatosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatic-steatosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,43,68,93,128,151,181,208,232,260,288,336,362],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100592440","acute-exercise-and-endogenous-glucose-production-in-type-2-diabetes-implications-for-glycemic-control-and-treatment-of-hepatic-steatosis-100592440",false,"NCT06993454","Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis","ACELERATE-P","Inclusion criteria for individuals with T2D and elevated liver fat ≥5.6%\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or (pre-menopausal) female, aged 25-55 years\n4. Body mass index (BMI) between 25 and 45 kg\u002Fm2\n5. Sedentary (1 day or less per week of structured exercise)\n6. Type 2 diabetes mellitus: HbA1c ≥7.5%\n7. Liver fat ≥5.6% based on MRI\n8. Weight stable (± 2 kg) for prior 3 months\n\nInclusion criteria for lean, healthy controls\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or (pre-menopausal) female, aged 25-55 years\n4. Body mass index (BMI) between 18.5 and 27.5 kg\u002Fm2\n5. Normal liver fat (FibroScan CAP \\\u003C249dB\u002Fm, \\\u003C5.6% liver fat based on MRI)\n6. Weight stable (± 2 kg) for prior 3 months\n7. Active (≥3 day\u002Fweek of structured exercise)\n\nExclusion Criteria\n\n1. Exclusion criteria for individuals with T2D and elevated liver fat ≥5.6% Currently taking insulin, incretin mimetics, and\u002For thiazolidinediones\n2. Any change in glucose-lowering medications within the previous three months.\n3. Inability to stop any medications which interfere with glucose metabolism for visits 4 and 7.\n4. Resting blood pressure ≥ 160\u002F100 mm Hg\n5. Triglycerides ≥ 500 mg\u002FdL\n6. Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol\n7. Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease)\n8. Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise testing\n9. Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma)\n10. Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next 6 months\n11. Post- or peri-menopausal women\n12. Partial and\u002For full hysterectomy (self-report)\n13. Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc\n14. Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting\n15. Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures\n16. New onset (\\\u003C3 months on a stable regime) hormone replacement therapy\n17. Current use of beta-adrenergic blocking agents\n18. Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months\n19. Previous bariatric or other surgery for obesity\n20. Abnormal blood count\u002Fanemia (hemoglobin \\\u003C12 g\u002Fdl in men or 11 g\u002Fdl in women; Hct \\\u003C34%), blood transfusion or blood donation within the last 2 months\n21. Current smokers (smoking within the past 3 months prior to screening visit, including any\u002Fall tobacco products)\n22. Current drug or alcohol abuse\u002Fdependence, or positive urine toxicology screen\n23. Alcohol consumption \\>7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month)\n24. Metal implants (pacemaker, aneurysm clips) based on investigator's judgment at screening\n25. Not physically capable of performing the exercise required of the study protocols\n26. Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening.\n27. Unable to tolerate MRI or claustrophobia.\n28. Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year\n29. Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy\n30. Unable or unwilling to communicate with staff or to provide written informed consent\n\nExclusion criteria for lean, healthy controls\n\n1. Currently taking insulin, injectable incretin mimetics, and\u002For thiazolidinediones\n2. Taking glucose-lowering medications\n3. HbA1c ≥ 5.7%; pre-diabetes, type 2 diabetes, or type 1 diabetes\n4. Resting blood pressure ≥ 160\u002F100 mm Hg\n5. Triglycerides ≥ 500 mg\u002FdL\n6. Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol\n7. Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease)\n8. Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise testing\n9. Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma)\n10. Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next year\n11. Post- or peri-menopausal women\n12. Partial and\u002For full hysterectomy (self-report)\n13. Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc\n14. Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting\n15. Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures\n16. New onset (\\\u003C3 months on a stable regime) hormone replacement therapy\n17. Current use of beta-adrenergic blocking agents\n18. Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months\n19. Previous bariatric or other surgery for obesity\n20. Increased liver function tests (AST\u002FALT\u002FGGT\u002For alkaline phosphatase greater than 2.5 times the upper limit of normal)\n21. Abnormal blood count\u002Fanemia (hemoglobin \\\u003C12 g\u002Fdl in men or 11 g\u002Fdl in women; Hct \\\u003C34%), blood transfusion or blood donation within the last 2 months\n22. Current smokers (smoking within the past 3 months prior to screening visit, including any\u002Fall tobacco products)\n23. Current drug or alcohol abuse\u002Fdependence, or positive urine toxicology screen\n24. Alcohol consumption \\>7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month)\n25. Metal implants (pacemaker, aneurysm clips) based on investigator's judgment at screening\n26. Not physically capable of performing the exercise required of the study protocols\n27. Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening.\n28. Unable to tolerate MRI or claustrophobia.\n29. Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year\n30. Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy\n31. Unable or unwilling to communicate with staff or to provide written informed consent",true,"ALL","25 Years","55 Years",{"count":21,"type":22},12,"ESTIMATED","INTERVENTIONAL",[25],"NA","The overall aim of this study is to investigate the effects of exercise on the amount of glucose that is made by the liver in people with and without Type 2 diabetes (T2D) and hepatic steatosis (fatty liver).",[28,29],"Type 2 Diabetes","Hepatic Steatosis","RECRUITING","2026-04-15",{"date":33,"type":34},"2026-04-17","ACTUAL",{"date":36,"type":34},"2025-04-25",{"date":38,"type":22},"2026-04",{"name":40,"class":41},"AdventHealth Translational Research Institute","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100631027","siemens-biomarker-multi-modality-100631027","NCT07495332","Siemens Biomarker Multi-modality","Inclusion Criteria:\n\n* Age of 18 years or older\n* Has clinically indicated CT schedule including the liver (with contrast or with and without contrast)\n* Patient eligible for MR imaging\n* History of chronic diffuse liver disease, steatotic liver disease, and\u002F or liver fibrosis\n* Capable of consent\n\nExclusion Criteria:\n\n* Contraindications to any of the required imaging examinations\n* BMI \\> 45 (based on MRI scanner capacity)","18 Years",{"count":51,"type":22},45,[25],"The purpose of this study is to see how well Photon Counting CT (PCCT) and ultrasound test results can find fat and scarring in the liver. They will be compared to MRI test results as the reference standard. Participants will get a regular CT scan on the PCCT scanner, plus a few extra pictures just for the study. They will also get an MRI, either on the same day or a different day, whichever is preferred. Participants will get an ultrasound on the same day as the MRI. If they have not had a hematocrit blood test in the past 24 hours, they will also receive one on the day of the CT scan.",[55,29],"Fatty Liver",[55,57,58],"Liver Fibrosis","Hepatic steatosis","2026-04-02",{"date":61,"type":34},"2026-04-03",{"date":63,"type":34},"2026-03-27",{"date":65,"type":22},"2027-05",{"name":67,"class":41},"Duke University",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":42},"100584593","phase-1-multiple-dose-study-for-a-new-medication-to-potentially-treat-liver-diseases-100584593","NCT06891365","Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases","Investigation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of NNC0581-0001 in Participants With Hepatic Steatosis and Suspected Steatohepatitis","Inclusion Criteria:\n\n* Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.\n* Male or female (of non-childbearing potential) aged 18-69 years (both inclusive) at the time of signing the informed consent.\n* Body mass index (BMI) greater than or equal to (\\>=) 25.0 at screening.\n* Liver fat content measured by magnetic resonance imaging - estimated proton density fat fraction (MRI-PDFF) \\>= 10 percent at screening.\n\nAdditional inclusion criteria for participants in the open-label liver biopsy cohort apply:\n\n* Alanine aminotransferase (ALT) in men greater than (\\>) 30 units per liter (U\u002FL), women \\> 19 U\u002FL\n* Liverstiffness, measured by FibroScan® (VCTE) \\> 8 kPa and less than (\\\u003C) 12 kPa\n* Informed consent obtained at screening for a liver biopsy to be performed at baseline and post-treatment.\n\nNote: Participants with confirmed metabolic dysfunction-associated steatohepatitis (MASH), based on a prior liver biopsy, can be included in the open-label cohort.\n\nExclusion Criteria:\n\n* Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n* Any laboratory safety parameter, at screening, outside the extended laboratory ranges, and considered clinically significant per the principal investigator (see laboratory provided reference ranges for specific values). Of note, re-screening or re-sampling is NOT allowed if the individual has failed one of the exclusion criteria related to the following laboratory parameters:\n* ALT \\>= 3 × upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) \\>= 3 × ULN\n* Bilirubin \\> 1.5 × ULN\n* Estimated glomerular filtration rate (eGFR) \\\u003C 50 milliliter per minute per 1.73 square meters (mL\u002Fmin\u002F1.73 m\\^2) at screening.\n\nAdditional exclusion criteria for participants in the open-label liver biopsy group apply:\n\n* Medical history of abnormal bleeding\n* BMI \\> 34.9 kilograms per square meters (kg\u002Fm\\^2)\n* Presence of ascites\n* Cirrhosis based on screening tests or historical biopsy\n* Lab abnormalities of platelets count \\\u003C 150 × 10\\^9 per liter or International Normalized Ratio (INR) \\> 1.2\n* Concomitant use of medication:\n* anticoagulants or herbal supplements with an anticoagulative effect (as judged by the principal investigator)\n* antiplatelet medications\n* exception for aspirin that must be stopped 5 days prior to procedure and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) that must not be taken within 3 days of the procedure.","64 Years",{"count":77,"type":22},48,[79],"PHASE1","The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of NNC0581-0001 in participants with hepatic steatosis and suspected steatohepatitis (increased liver fat and suspected inflammation). NNC0581-0001 will be given in 2 different dose levels as injection under the skin (once per month for 3 months). Participants will either get NNC0581-001 or Placebo (dummy treatment). Which treatment participants get is decided by chance. NNC0581-0001 is a new medicine which cannot be prescribed by doctors. The study will last about 58 weeks.",[82,29],"Healthy Volunteers","2026-04-01",{"date":85,"type":34},"2026-04-07",{"date":87,"type":34},"2025-03-12",{"date":89,"type":22},"2027-11-15",{"name":91,"class":92},"Novo Nordisk A\u002FS","INDUSTRY",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":42},"100629981","phase-2-tesamorelin-for-reduction-of-liver-fat-in-adults-with-fatty-liver-disease-mock-study-100629981","NCT07481734","Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Tesamorelin (GHRH Analog) for Reducing Hepatic Steatosis in Adults With Metabolic Associated Steatotic Liver Disease (MASLD)","TESA-LIVER","Inclusion Criteria:\n\n* Adults age 18 to 75 years, able to provide informed consent.\n* Evidence of hepatic steatosis consistent with MASLD\u002FNAFLD, defined as MRI-PDFF \\>=10% at screening (or equivalent imaging documentation if MRI-PDFF was performed within the prior 8 weeks).\n* Fibrosis risk compatible with non-cirrhotic disease (e.g., FibroScan liver stiffness below a prespecified threshold and no clinical evidence of portal hypertension).\n* Stable body weight (+\u002F-5%) for at least 3 months prior to screening.\n* If on diabetes, lipid-lowering, antihypertensive, or weight-loss medications, regimen is stable for at least 3 months prior to screening and expected to remain stable through week 52.\n* Willingness and ability to self-administer daily subcutaneous injections (or have a trained caregiver).\n* For participants of childbearing potential: agreement to use reliable contraception during treatment and for 30 days after the last dose; negative pregnancy test at screening and baseline.\n\nExclusion Criteria:\n\n* Significant alcohol consumption consistent with alcohol-associated liver disease (e.g., \\>20 g\u002Fday for women or \\>30 g\u002Fday for men for sustained periods).\n* Other chronic liver diseases (e.g., chronic hepatitis B, chronic hepatitis C with viremia, autoimmune hepatitis, Wilson disease, hemochromatosis, alpha-1 antitrypsin deficiency).\n* Known cirrhosis or decompensated liver disease; or biopsy-proven stage 4 fibrosis if baseline biopsy is performed.\n* Poorly controlled diabetes or conditions increasing ocular risk (e.g., HbA1c at or above a protocol threshold; active\u002Funtreated diabetic retinopathy).\n* Use of exogenous growth hormone or GHRH analogs within the past 12 months.\n* Chronic systemic corticosteroids or chronic use of medications known to induce or worsen steatosis or liver injury (e.g., amiodarone, tamoxifen, methotrexate).\n* Active malignancy or high risk for recurrence judged unsafe by investigators.\n* Contraindications to MRI (e.g., certain implanted devices) if MRI-PDFF is required.\n* Pregnancy or breastfeeding.\n* Known hypersensitivity to tesamorelin or formulation excipients (e.g., mannitol).\n* Bariatric surgery within the last 12 months, or planned bariatric surgery during the study period.","75 Years",{"count":103,"type":22},120,[105],"PHASE2","This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease. Participants receive tesamorelin or matching placebo for 52 weeks, with standardized lifestyle counseling in both groups. Liver fat is quantified by MRI-proton density fat fraction (MRI-PDFF). Key safety monitoring includes glucose metrics and IGF-1.",[108,109,29],"Metabolic Associated Steatotic Liver Disease","Nonalcoholic Steatohepatitis",[111,112,113,114,115,116,117,118],"Tesamorelin","GHRH analog","growth hormone axis","hepatic fat fraction","MRI-PDFF","transient elastography","teatohepatitis","fibrosis","2026-03-14",{"date":121,"type":34},"2026-03-19",{"date":123,"type":34},"2026-02-02",{"date":125,"type":22},"2028-02-17",{"name":127,"class":92},"Hudson Biotech",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100617579","phase-2-a-clinical-trial-of-longqi-jiangzhi-decoction-against-non-alcoholic-fatty-liver-disease-100617579","NCT07320456","A Clinical Trial of Longqi Jiangzhi Decoction Against Non-alcoholic Fatty Liver Disease","Effect of Longqi Jiangzhi Decoction on Non-alcoholic Fatty Liver Disease: a Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age 18-50 years, both genders eligible;\n2. Meets the diagnostic criteria for NAFLD;\n3. Meets the diagnostic criteria for Traditional Chinese Medicine Spleen Deficiency and Damp-Heat Syndrome;\n4. Has significant risk factors: CAP≥238dB\u002Fm, Body Mass Index (BMI) ≥23 kg\u002Fm²;\n5. Has not received any anti-NAFLD medication treatment in the past month;\n6. Normal major organ function, including heart, kidney, and liver functions, specifically: no significant abnormalities on electrocardiogram; normal serum creatinine and urea nitrogen; normal serum bilirubin and albumin levels;\n7. Has sufficient cognitive and understanding abilities to comprehend the study content and its potential risks and benefits;\n8. Voluntarily participates in the study and signs an informed consent form.\n\nExclusion Criteria:\n\n1. Has liver steatosis due to other definitive causes, such as alcoholic liver disease, drug-induced liver injury, viral hepatitis infections (e.g., hepatitis B, hepatitis C, etc.);\n2. Has other serious liver diseases, such as autoimmune liver diseases, primary biliary cholangitis, Wilson's disease, etc.;\n3. Has severe dysfunction of major organs such as the heart, kidneys, lungs, etc., such as severe heart failure (NYHA functional classification III or above), renal failure (glomerular filtration rate eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²), acute exacerbation of chronic obstructive pulmonary disease, etc.;\n4. Has other serious systemic diseases, such as malignant tumors, active systemic lupus erythematosus, etc.;\n5. Known allergy or intolerance to any component of the study medication;\n6. Has participated in another clinical trial within the last three months;\n7. Pregnant women, lactating women, or women of childbearing age who refuse to use effective contraception during the trial;\n8. Has severe mental illness or behavioral disorders that may affect adherence to the study protocol;\n9. Other conditions that the researcher considers unsuitable for participation in this study.","50 Years",{"count":137,"type":22},80,[105],"The goal of this clinical trial is to learn if Longqi Jiangzhi decoction works to treat non-alcoholic fatty liver disease in adults. It will also learn about the safety of drug Longqi Jiangzhi decoction. Researchers will compare drug Longqi Jiangzhi decoction to a placebo (a look-alike substance that contains no drug) to see if drug Longqi Jiangzhi decoction works to treat non-alcoholic fatty liver disease. Participants will: Take drug Longqi Jiangzhi decoction or a placebo every day for eight weeks Keep a record of their symptoms and the degree of hepatic steatosis before and after the treatment.",[29],"NOT_YET_RECRUITING","2025-12-21",{"date":144,"type":34},"2026-01-06",{"date":146,"type":22},"2025-12-29",{"date":148,"type":22},"2026-07-31",{"name":150,"class":41},"Shanghai Municipal Hospital of Traditional Chinese Medicine",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100607715","quantitative-ultrasounddeepusff-vs-mri-pdff-for-liver-fat-assessment-in-masld-100607715","NCT07192159","Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD","Evaluation of a Quantitative Ultrasound Model(DeepUSFF) for Liver Fat Quantification in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Prospective Study Using MRI-PDFF as the Reference Standard","DeepUSFF","Inclusion Criteria:\n\n* Patients with clinically suspected MASLD based on abnormal ultrasound or liver function tests requiring liver ultrasound or MRI examination\n* BMI ≥25 kg\u002Fm² or waist circumference \\>90 cm (male) or \\>80 cm (female), suggesting high likelihood of fatty liver disease\n* Living liver transplant donors requiring preoperative liver ultrasound or MRI examination\n* Age ≥18 years\n* Understanding and signing informed consent\n\nExclusion Criteria:\n\n* Significant alcohol consumption in the past 2 years:\n\nMale: ≥30-60g\u002Fday average alcohol intake Female: ≥20-50g\u002Fday average alcohol intake\n\n-Chronic liver disease:\n\nHistological diagnosis of chronic liver disease HBsAg positive Anti-HCV positive Other suspected chronic liver diseases\n\n-Liver failure:\n\nSerum albumin \\\u003C3.2 g\u002FdL INR \\>1.3 Direct bilirubin \\>1.3 mg\u002FdL\n\n* History of esophageal varices, ascites, hepatic encephalopathy, or acute biliary obstruction\n* History of liver cancer diagnosis or treatment\n* History of liver surgery\n* Pregnancy\n* Inability to obtain adequate liver ultrasound imaging:\n\nPatient cooperation impossible Inadequate image acquisition as determined by investigator\n\n-Inability to obtain adequate liver MRI imaging: Patient cooperation impossible Severe obesity preventing MRI examination MRI contraindications (cardiac pacemaker, etc.) Other factors preventing adequate imaging as determined by investigator",{"count":160,"type":22},62,[25],"This multicenter prospective study aims to evaluate the correlation between quantitative ultrasound fat fraction (USFF) and MRI-PDFF (Proton Density Fat Fraction) for liver fat quantification in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The study will compare the diagnostic accuracy of quantitative ultrasound imaging against MRI-PDFF as the reference standard.",[164,29,165],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Liver Disease Parenchymal",[167,168,115,169,58,170],"Metabolic dysfunction-associated steatotic liver disease","Quantitative ultrasound","Liver fat quantification","Deep learning","2025-09-17",{"date":173,"type":34},"2025-09-25",{"date":175,"type":34},"2025-06-24",{"date":177,"type":22},"2026-06-30",{"name":179,"class":41},"Seoul National University Hospital",2,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":188,"maxAge":49,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":193,"conditions":194,"keywords":197,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":42},"100511160","phase-3-effect-of-amino-acids-on-hepatic-fat-content-in-adolescents-aminos-study-100511160","NCT05935826","Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)","AMINOS","Inclusion Criteria\n\n* Ages 13-18, Tanner stage 4-5\n* Suspected or diagnosed with NAFLD per fibroscan or liver biopsy within 6 months prior to enrollment as long as participants have not lost more than 5% of total body weight. Their MRI liver fat \\>5.5%\n* Diagnosis of non-alcoholic fatty liver disease (NAFLD) per hepatologist\n* Sedentary- less than 3 hours of moderate (jogging, swimming, etc.) exercise a week\n* BMI equal or greater than the 85th percentile for age and gender, this is overweight and obese categories\n\nExclusion Criteria\n\n* Use of medications known to affect insulin sensitivity: metformin, oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressant agents, HIV medications.\n* Currently pregnant or breastfeeding women. Development of pregnancy during the study period will necessitate withdrawal from the study\n* Severe illness requiring hospitalization within 60 days\n* Diabetes, defined as Hemoglobin A1C \\> 6.4%\n* BMI percentile less than the 85th percentile for age and sex. Waist circumference \\>200 cm\n* Anemia, defined as Hemoglobin \\\u003C 11 mg\u002FdL\n* Diagnosed major psychiatric or developmental disorder limiting informed consent\n* Implanted metal devices that are not compatible with MRI\n* Use of blood pressure medications\n* Known liver disease other than NAFLD or AST or ALT \\>150 IU\u002FL","13 Years",{"count":190,"type":22},55,[192],"PHASE3","Participants 13-18 years of age with extra fat stored in the liver will be randomly assigned to a protein supplement or placebo \"fake supplement\" for 2 months to see if the participants who get the protein supplement have less fat in the liver compared to participants who were in the placebo group. After the 2 month intervention, all participants can continue the study and will all receive the protein supplement for an additional 10-months.",[29,195,196],"NAFLD","Adolescent Obesity",[198],"Amino Acid Supplement","2025-08-21",{"date":201,"type":34},"2025-08-28",{"date":203,"type":34},"2024-06-18",{"date":205,"type":22},"2026-08-31",{"name":207,"class":41},"University of Colorado, Denver",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":42},"100546382","benefit-of-a-hospital-intervention-in-patients-with-hepatic-steatosis-100546382","NCT06394206","Benefit of a Hospital Intervention in Patients With Hepatic Steatosis","BIPEH","Inclusion Criteria:\n\n* Patients seen in outpatient gastroenterology clinics with hepatic steatosis.\n* Diagnosed with hepatic steatosis through ultrasound or abdominal CT scan\n* Mild to moderate fibrosis as assessed by elastography or FibroScan (F1-F3) or with a Fibrosis-4 (FIB-4) Index less than 3.5.\n* Signature of informed consent for study inclusion, either by the participant themselves or by their legal representative.\n\nExclusion Criteria:\n\n* Patients who do not have any hepatic imaging test conducted in the last 5 years.\n* Conditions other than hepatic steatosis requiring gastroenterological follow-up.\n* Abusive alcohol consumption, defined as weekly intake of \\> 50 g in women and more than 70 g in men.\n* Cognitive or affective disorders limiting the ability to cooperate with study procedures.\n* Participation in another clinical trial involving experimental intervention during the period of this trial and\u002For establishing visit schedules incompatible with this trial.","80 Years",{"count":217,"type":22},86,[25],"The objective of this clinical trial is to determine whether a specialized consultation for controlling metabolic syndrome effectively treats hepatic steatosis in adults. The primary questions it aims to answer are:\n\n• Does this specialized consultation increase the number of patients with hepatic steatosis who show improvement after one year of clinical follow-up in said consultation?\n\nThe improvement of the disease will be assessed through the following parameters:\n\n* liver laboratory tests\n* weight loss\n* improvement in cholesterol and triglyceride levels. Researchers will compare follow-up in the specialized consultation to standard follow-up to assess the effectiveness of the specialized consultation in treating hepatic steatosis.\n\nParticipants will be randomly assigned to two groups. The first group will be visited in the specialized consultation every three months for one year and will continue to receive the rest of their follow-up visits. The second group will undergo their usual follow-up visits but will not be visited in the specialized consultation.",[29],[55,222],"Metabolic Syndrome","2025-02-10",{"date":225,"type":34},"2025-02-12",{"date":227,"type":22},"2025-12",{"date":229,"type":22},"2027-12",{"name":231,"class":41},"Consorci Sanitari de l'Alt Penedès i Garraf",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":242,"phases":4,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":42},"100514162","association-of-hscar-with-mafld-and-liver-fibrosis-a-cross-sectional-study-100514162","NCT05974904","Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study","Association of High-sensitivity C-reactive Protein to Albumin Ratio with Metabolic Dysfunction-associated Fatty Liver Disease and Liver Fibrosis: a Cross-sectional Study","Inclusion Criteria:\n\n* Total participants from NHANES 2017-2020\n* Participants diagnosed with MAFLD. Metabolic dysfunction-associated fatty liver disease (MAFLD) is the term used to describe hepatic steatosis in the presence of metabolic abnormalities, excess weight, obesity, or type 2 diabetic mellitus.\n\n  1. Diagnosis of diabetes mellitus: (1) taking glucose-lowering drugs; (2) HbA1c ≥ 6.5% (48 mmol\u002Fmol); (3) fasting plasma glucose ≥ 7.0 mmol\u002FL (126 mg\u002FdL); (4) 2-hour plasma glucose (2hPG) ≥ 11.1 mmol\u002FL (200 mg\u002FdL).\n  2. Overweight or obesity: defined as BMI≥25 kg\u002Fm2 in Caucasians or BMI≥23 kg\u002Fm2 in Asians\n  3. If presence of at least two metabolic risk abnormalities:\n\n     * Waist circumference≥102\u002F88 cm in Caucasian men and women (or≥90\u002F80 cm in Asian men and women)\n     * Blood pressure≥130\u002F85 mmHg or specific drug treatment\n     * Plasma triglycerides≥150 mg\u002Fdl (≥1.70 mmol\u002FL) or specific drug treatment\n     * Plasma HDL-cholesterol \\\u003C40 mg\u002Fdl (\\\u003C1.0 mmol\u002FL) for men and \\\u003C50 mg\u002Fdl (\\\u003C1.3 mmol\u002FL) for women or specific drug treatment\n     * Prediabetes (i.e., fasting glucose levels 100 to 125 mg\u002Fdl \\[5.6 to 6.9 mmol\u002FL\\], or 2-hour post-load glucose levels 140 to 199 mg\u002Fdl \\[7.8 to 11.0 mmol\\] or HbA1c 5.7% to 6.4% \\[39 to 47 mmol\u002Fmol\\])\n     * Homeostasis model assessment of insulin resistance score≥2.5\n     * Plasma high-sensitivity C-reactive protein level \\>2 mg\u002FL\n\nExclusion Criteria:\n\n* Liver ultrasound data not available\n* participants without complete clinical data\n* participants under 18 years old\n* participants with cancer.","90 Years",{"count":241,"type":22},7000,"OBSERVATIONAL","The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD).\n\nThe main question\\[s\\] it aims to answer are:\n\n\\[question 1\\] Can hsCAR serve as a clinical indicator to determine whether a patient has MAFD? \\[question 2\\] Can hsCAR determine whether MAFLD patients are complicated with liver fibrosis?",[245,29,57],"Metabolic Dysfunction-associated Fatty Liver Disease",[247,248,249,250,251,252],"high-sensitivity C-reactive protein to albumin ratio","metabolic dysfunction-associated fatty liver disease","National Health and Nutrition Examination Survey","control attenuation parameter","liver stiffness measurement","inflammation",{"date":225,"type":34},{"date":255,"type":34},"2023-07-18",{"date":257,"type":22},"2026-12-28",{"name":259,"class":41},"Chongqing Medical University",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":242,"phases":4,"briefSummary":269,"conditions":270,"keywords":274,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":4},"100572916","efficacy-of-sodium-glucose-cotransporter-2-inhibitors-on-non-alcoholic-fatty-liver-disease-100572916","NCT06739486","Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease","Inclusion Criteria:\n\n* age \\>18 years\n* both sex\n\nExclusion Criteria:\n\n* alcohol drinker\n* any cause of liver affection (hepatitis, autoimmune…etc)\n* patients with kidney function affection","65 Years",{"count":268,"type":22},100,"evaluate the effectiveness of sodium-glucose cotransporter-2 (SGLT.2) inhibitors in improving hepatic steatosis and hepatic fibrosis using imaging biomarkers and histopathology in patients with non-alcoholic fatty liver disease",[271,29,272,273],"Non Alcholic Fatty Liver Disease","Hepatic Fibrosis","NAFLD (Nonalcoholic Fatty Liver Disease)",[195,275,58,276,277,278],"Non alcoholic fatty liver disease","Hepatic fibrosis","Na glucose cotransporter 2 inhibitors","SGLT-2 inhibitors","2024-12-17",{"date":281,"type":34},"2024-12-18",{"date":283,"type":22},"2024-12-20",{"date":285,"type":22},"2025-12-20",{"name":287,"class":41},"Assiut University",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":295,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":242,"phases":4,"briefSummary":298,"conditions":299,"keywords":316,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":42},"100569420","osaka-cardiometabolic-epidemiological-study-ohtori-study-part-2-100569420","NCT06694012","Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2","OCES-2","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n* Women who may be pregnant","20 Years",{"count":297,"type":22},2000,"The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and cardiovascular disease in a prospective cohort study of Japanese men and women. The investigators will also investigate novel risk factors for metabolic and cardiovascular disease using molecular weight-based metallomics analysis.",[300,28,301,302,303,304,305,306,307,308,309,310,311,312,313,314,222,29,315],"Type 2 Diabetes Mellitus (T2DM)","Diabetes Mellitus","Hypertension","Hyperglycemia","Hyperlipidemia","Dyslipidemia","Hyperuricemia or Gout","Hyperuricemia, Gout","Obesity","Obesity\u002FEpidemiology","Obesity, Abdominal","Central Obesity","Visceral Fat","Chronic Kidney Disease(CKD)","Atherosclerosis","Insulin Sensitivity\u002FResistance",[317,302,304,305,318,319,320,321,322,323,324,222,325,326],"Type 2 Diabetes Mellitus","Hyperuricemia","obesity","Abdominal obesity","Visceral fat","Visceral adiposity","Chronic Kidney Disease","Japanese","Insulin Sensitivity","Insulin Resistance","2024-11-29",{"date":329,"type":34},"2024-12-04",{"date":331,"type":34},"2024-11-01",{"date":333,"type":22},"2050-03-31",{"name":335,"class":41},"Osaka Metropolitan University",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":17,"minAge":344,"maxAge":345,"enrollmentInfo":346,"targetDuration":4,"studyType":23,"phases":348,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":42},"100476189","phase-2-soluble-fibre-supplementation-in-nafld-100476189","NCT05480696","Soluble Fibre Supplementation in NAFLD","The Efficacy of Soluble Fibre Supplementation for the Treatment of Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)","FIND","Inclusion Criteria:\n\n* Children ages 8-17 years\n* Diagnosed with obesity (BMI ≥2 standard deviations above WHO reference median)\n* Enrolled in GHWM Clinic\n* Clinical evidence of NAFLD (elevation of ALT, greater than 2x upper-limit-of-normal (ULN) \\[ALT\\>80 IU\u002FL for 8-17 years of age\\], and hepatic steatosis measured as part of clinic enrolment).\n\nExclusion Criteria:\n\n* Type 1, Type 2 diabetes mellitus (T1DM, T2DM)\n* Contraindications to having MRI (claustrophobia, metal implant, recent tattoo, weight \\> 300lbs)\n* Concomitant use of other fibre supplements\n* Medications known to affect hepatic fat content, taken within the past year (i.e., glucocorticoids, anabolic steroids, tetracycline, anticonvulsants, antipsychotics, glucose- lowering medications)\n* Presence of another known cause of liver disease\n* Known allergy or hypersensitivity to OF-INU supplementation\n* Self-reported alcohol intake \\>7 drinks\u002Fweek or 3 drinks\u002Fday","8 Years","17 Years",{"count":347,"type":22},60,[105],"The FIND study will look at the effect of a nutritional mixed fibre supplement, oligofructose and inulin (OF+INU), on children with non-alcoholic fatty liver disease. In this randomized, double- blind controlled trial, subjects will be given a supplement, in the form of oral pills, and will have bloodwork performed, their diets analyzed, and liver fat measured at several timepoints. Liver fat will be measured by using a specialized MRI device located at St. Joseph's Hospital. Subjects will be recruited from the Children's Exercise and Nutrition Clinic.",[351,352,29],"Non-Alcoholic Fatty Liver Disease","Non Alcoholic Steatohepatitis","2024-11-08",{"date":355,"type":34},"2024-11-12",{"date":357,"type":34},"2022-09-09",{"date":359,"type":22},"2027-03",{"name":361,"class":41},"McMaster University",{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":101,"enrollmentInfo":370,"targetDuration":4,"studyType":23,"phases":372,"briefSummary":373,"conditions":374,"keywords":377,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":386,"locationsCount":42},"100563718","hyperbaric-oxygen-therapy-for-metabolic-dysfunction-associated-steatotic-liver-diseases-100563718","NCT06619808","Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases","Efficacy and Safety of Hyperbaric Oxygen Therapy in Adult Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD) Patients : a Randomized Controlled Trial","MASLD","Inclusion Criteria:\n\n* Metabolic dysfunction-associated steatotic liver disease patients\n\nExclusion Criteria:\n\n* Participants are unfit for hyperbaric treatment.\n* Participants with prior oxygen therapy within the last 6 months.\n* Participants with history of viral hepatitis, hemochromatosis, Wilson disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction, alpha-1 antitrypsin deficiency.\n* Participants with severe organ dysfunctions or malignant tumors.\n* Participants have weight loss plan or major operations within the last 6 months.\n* Participants are unable to provide informed consent or currently participating in or has within the last 3 months participated in any other clinical trial.\n* Participants are pregnant or lactating.\n* Participants with claustrophobia or that cannot decompress properly.",{"count":371,"type":22},150,[25],"The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main questions it aims to answer are:\n\nDoes HBOT decreases the fat content and fibrosis state of liver in adult MASLD patients? Does HBOT improves the liver function and metabolic condition in adult MASLD patients?\n\nParticipants will:\n\nReceive HBOT for 20 times in 1 month or recerive regular drug; Visit the clinic for checkups and tests at the starting, ending of the therapy and 6 month after the therapy.",[375,29,376],"Metabolic Dysfunction-associated Steatotic Liver Disease","Non-alcoholic Fatty Liver Diseases",[375,378,376,379],"Hyperbaric Oxygen Therapy","Oxygen Therapy","2024-09-28",{"date":382,"type":34},"2024-10-01",{"date":384,"type":34},"2024-07-29",{"date":205,"type":22},{"name":387,"class":41},"Jinling Hospital, China"]